GSE132554 Combined proteomics and miRNomics of a glioblastoma immunotherapy cohort reveal resistance factor candidates and potential counterstrategies

Contributors : Friedrich Erhart ; Matthias Hackl ; Hannes Hahne ; Johanna Buchroithner ; Cheng Meng ; Simone Klingenbrunner ; Rene Reitermaier ; Katrin Fischhuber ; Susanna Skalicky ; Walter Berger ; Sabine Spiegl-Kreinecker ; Daniela L ötsch ; Gerda Ricken ; Bernhard Kuster ; Adelheid Wöhrer ; Georg Widhalm ; Johannes Hainfellner ; Thomas Felzmann ; Alexander M Dohnal ; Christine Marosi ; Carmen VisusSeries Type : Non-coding RNA profiling by high throughput sequencingOrganism : Homo sapiensGlioblastoma is the most prevalent and aggressive brain cancer. With a median overall survival of ~15-20 months under standard therapy, novel treatment approaches are desperately needed. A recent phase II clinical trial with a personalized immunotherapy based on tumor lysate-charged dendritic cells (DCs), however, failed to prolong survival. Here, we investigated tumor tissue from patients from this trial to explore glioblastoma (immuno)resistancesurvival-related factors. and strategies to overcome them. We followed an innovative approach of combining mass spectrometry-based quantitative proteomics (n=36) with microRNA sequencing plus RT-qPCR (n=38). Protein quantification identified e.g. huntingtin interacting protein 1 (HIP1), retinol binding protein 1 (RBPP1), ferritin heavy chain (FTH1) and focal adhesion kinase 2 (FAK2) as resistance factor candidates. MicroRNA analysis identified miR-216b, miR-216a, miR-708 and let-7i as molecules potentially associated with ov...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Non-coding RNA profiling by high throughput sequencing Homo sapiens Source Type: research